Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 clinical trial evaluating olomorasib as a monotherapy in...

Related Keywords

United States ,American ,Joe Fletcher ,David Hyman ,Prnewswire Eli Lilly ,Eli Lilly ,Timothy Burns ,Exchange Commission ,American Society Of Clinical Oncology ,Merck Sharp Dohme ,Lilly United States ,Linkedin ,Facebook ,Merck Co Inc ,Cancer Research ,Instagram ,Clinical Oncology ,Associate Professor ,Pittsburgh Medical Center Hillman Cancer ,Merck Sharp ,Private Securities Litigation Reform Act ,United States Securities ,